Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
about
Aliskiren: the first renin inhibitor for clinical treatmentPharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtypeCardiac-specific overexpression of angiotensin II AT2 receptor causes attenuated response to AT1 receptor-mediated pressor and chronotropic effectsAngiotensin II receptor antagonists and hypertension.Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteersSummertime dosage-dependent hypersensitivity to an angiotensin II receptor blockerA pharmacodynamic study of SR 47436, a selective AT1 receptor antagonist, on blood pressure in conscious cynomolgus monkeys.Evaluation of the angiotensin challenge methodology for assessing the pharmacodynamic profile of antihypertensive drugs acting on the renin-angiotensin system.Endogenous angiotensin II levels and the mechanism of action of angiotensin-converting enzyme inhibitors and angiotensin receptor type 1 antagonists.Experience with angiotensin II antagonists in hypertensive patients.Pharmacokinetic evaluation of losartan.Angiotensin II antagonists.Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy.New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors.Angiotensin II receptor antagonists: the prototype losartan.Losartan: first of a new class of angiotensin antagonists for the management of hypertension.Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans.Comparison of the regional haemodynamic effects of the AT1-receptor antagonists, losartan and EXP 3174, in water-deprived Brattleboro ratsHaemodynamic, renal sodium handling, and neurohormonal effects of acute administration of low dose losartan, an angiotensin II receptor antagonist, in preascitic cirrhosis.Comparative effects of chronic ACE inhibition and AT1 receptor blocked losartan on cardiac hypertrophy and renal function in hypertensive patients.Chronic administration of losartan, an angiotensin II receptor antagonist, is not effective in reducing portal pressure in patients with preascitic cirrhosis.The pharmacokinetics of irbesartan in renal failure and maintenance hemodialysis.Angiotensin II-receptor antagonist losartan does not prevent nitroglycerin tolerance in patients with coronary artery disease.The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.TAK-272 (imarikiren), a novel renin inhibitor, improves cardiac remodeling and mortality in a murine heart failure model
P2860
Q28272666-DA329591-ADB3-4A32-BE71-019A938EA158Q28378367-DD01FA77-863E-418E-8444-53224ED6C6F3Q28505671-CF644EC9-4C64-4F48-B312-C80EA5F414CDQ33697688-5B38F8C9-20FA-4091-8E4E-463F3E2C54A8Q34347645-EBB0D010-E884-4CC2-A287-50C4278E5A44Q35657292-6BC9A3DE-F514-4F85-B803-F4206EFDC464Q35874306-8E832AB2-8365-413A-8AFC-F0EE7EAFD0D5Q36053876-143EF0F5-2D0D-43E0-A816-B870671F11E3Q37818472-719764AB-27ED-4883-B113-AD714D5A49C4Q37818477-CEE6523E-B8BF-49F4-B678-6B31E1DFF83EQ37854746-8097FFEC-6B7C-4358-AF5A-FDB119A53C91Q40794697-95178E65-6979-4BBB-9872-2E89BAF8663BQ40811095-8381CF07-9DBD-4F27-9203-D5F25CE83376Q40813465-3E5FAA07-19C3-4B75-8EB4-7F654BE6659EQ41102136-3F0FB14B-613D-437A-AAEC-F0204F49863DQ41227362-AB9631D2-3327-4247-9D3B-926972FAF575Q42084127-C918FA76-9483-415D-BD19-EB7E229FB0DFQ42714643-411641E5-F54E-40B7-B2BA-658E64C7A652Q43086634-CD9719C8-B8FD-4810-A1F3-85F454BE5B3DQ43890925-5C650DF1-E3E9-473D-8D96-CC3870A5AE49Q44815604-45CB3E15-8797-4361-AE4F-C423E5A545DDQ45109095-5B68483E-6D7A-4F1C-99CD-3FF7D3B010E5Q45270475-31E0C754-7DBD-49CD-B804-C625C0103546Q54029916-0976ADF5-1B69-435E-BD87-DD5833681FE1Q58794179-AEF34600-3DDE-4B35-8394-45D0165ED84A
P2860
Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@en
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@nl
type
label
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@en
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@nl
prefLabel
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@en
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@nl
P2093
P356
P1433
P1476
Oral administration of DuP 753 ...... xogenous angiotensin I and II.
@en
P2093
Borland RM
Brunner HR
Christen Y
Nussberger J
Timmermans PB
P304
P356
10.1161/01.CIR.83.4.1333
P407
P577
1991-04-01T00:00:00Z